

CORRECTION

Open Access



# Correction to: High-affinity peptide ligand LXY30 for targeting $\alpha 3\beta 1$ integrin in non-small cell lung cancer

Wenwu Xiao<sup>1†</sup>, Weijie Ma<sup>2†</sup>, Sixi Wei<sup>2,3</sup>, Qianping Li<sup>2,4</sup>, Ruiwu Liu<sup>1</sup>, Randy P. Carney<sup>5</sup>, Kevin Yang<sup>2,6</sup>, Joyce Lee<sup>7</sup>, Alan Nyugen<sup>1</sup>, Ken Y. Yoneda<sup>8,9</sup>, Kit S. Lam<sup>1,2\*</sup> and Tianhong Li<sup>2,9\*</sup>

**Correction to: J Hematol Oncol (2019) 12:56**

<https://doi.org/10.1186/s13045-019-0740-7>

The original article [1] contains an error in Fig. 2 whereby Fig. 2d has mistakenly been omitted. Figure 2 can be viewed in its entirety – including Fig. 2d – in this Correction article.

## Author details

<sup>1</sup>Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA. <sup>2</sup>Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA. <sup>3</sup>Present Address: Department of Biochemistry, Hospital Affiliated to Guizhou Medical University, Guiyang, Guizhou, China. <sup>4</sup>Present Address: Department of Cardiothoracic Surgery, Shanghai Jiaotong University Affiliated Sixth People's Hospital, 600 Yi-Shan Road, Shanghai 200233, China. <sup>5</sup>Department of Biomedical Engineering, University of California Davis, Davis, CA, USA. <sup>6</sup>Present Address: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. <sup>7</sup>Department of Pharmacy, University of California Davis Health System, Sacramento, CA 95817, USA. <sup>8</sup>Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA, USA. <sup>9</sup>Department of Internal Medicine, Veterans Affairs Northern California Health Care System, Mather, CA, USA.

Received: 2 July 2019 Accepted: 2 July 2019

Published online: 26 July 2019

## Reference

1. Xiao W, Ma W, Wei S, Li Q, Liu R, Carney RP, et al. High-affinity peptide ligand LXY30 for targeting  $\alpha 3\beta 1$  integrin in non-small cell lung cancer. *J Hematol Oncol*. 2019;12:56 <https://doi.org/10.1186/s13045-019-0740-7>.

\* Correspondence: [kslam@ucdavis.edu](mailto:kslam@ucdavis.edu); [thli@ucdavis.edu](mailto:thli@ucdavis.edu)


<sup>†</sup>Wenwu Xiao and Weijie Ma contributed equally to this work.

<sup>1</sup>Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA

<sup>2</sup>Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA

Full list of author information is available at the end of the article





**Fig. 2** Characterization of tumor derived exosomes and EVs. The size and morphology of exosomes were evaluated by dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA) (a) and transmission electron microscopy (TEM) (b), respectively. The yield of DNA was 3.4-fold higher in LXY30-enriched exosomes than in S-LXY30-enriched exosomes (3.4 ± 0.7 vs 1.0 ± 0.2 ng/μL, *p* = 0.014) (c). Driven mutations (EGFR L858R and T790 M in H1975) were detected by PCR and Sanger sequencing in the DNA isolated from LXY30 exosomes (d)